Key result
Apixaban showed superiority over warfarin and other direct oral anticoagulants in terms of efficacy and safety in patients with isolated atrial fibrillation and those with concomitant diseases.
Why the study?
Multimorbidity is common and carries a substantially higher risk of death in patients with AF, highlighting the need to evaluate antithrombotic therapy in this population.
Does apixaban improve efficacy and safety compared to warfarin and other DOACs in multimorbid patients with atrial fibrillation?
Does apixaban improve efficacy and safety compared to warfarin and other DOACs in multimorbid patients with atrial fibrillation?
Apixaban is highlighted as the preferable choice for treating multimorbid AF patients due to its superior efficacy and safety profile compared to warfarin and other DOACs.
Answers are grounded in this paper and cite their sources.
May inform DOAC selection in multimorbid AF; hypothesis-generating pending dedicated prospective trials.
Clinical practice and ongoing scientific research in recent years show the importance of the problem of multimorbidity in atrial fibrillation (AF). The prevalence of AF in the general population is 1–2%, while the frequency of its occurrence increases with age – from less than 0.5% at the age of 40–50 to 5–15% at the age of 80. Only 19.6% of patients with AF have no comorbidities, 69.3% of patients have 1 to 3 comorbidities, and 11.1% of patients with AF had 4 and more comorbidities. In patients with AF and with 4 and more comorbidities, the risk of death from all causes is almost seven times higher than in patients without comorbidities. As shown by the post hoc analysis of the ARISTOTLE study, apixaban was equally effective and safe in both patients without concomitant pathology and in muliborbid patients. The efficacy and safety of apixaban has been shown in AF and concomitant arterial hypertension, heart failure, coronary heart disease, including in patients with acute coronary syndrome, diabetes mellitus, chronic kidney disease and chronic obstructive pulmonary disease. The data of scientific research in recent years are reflected in the recommendations of the Ministry of Health of the Russian Federation on AF (2020), which presents a separate section on the management of patients with concomitant diseases. It is emphasized that apixaban has shown its superiority over warfarin and other direct oral anticoagulants in terms of efficacy and safety, both in isolated AF and in patients with concomitant diseases, which makes its choice preferable in the treatment of multimirbidity AF patients.
No takes yet. Share an insight, caveat, or question.
Остроумова et al. (2021) conducted a review in Atrial fibrillation with multimorbidity. Apixaban vs. Warfarin and other direct oral anticoagulants was evaluated. Apixaban showed superiority over warfarin and other direct oral anticoagulants in terms of efficacy and safety in patients with isolated atrial fibrillation and those with concomitant diseases.
Synapse has enriched 10 related papers. Consider them for comparative context: